Alligator Bioscience AB (OSTO:ATORX) Cyclically Adjusted FCF per Share: kr-1,963.08 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Alligator Bioscience AB Cyclically Adjusted FCF per Share?

Alligator Bioscience AB OSTO:ATORX -3.30% Cyclically Adjusted FCF per Share is kr-1,963.08 as of Jun. 2026. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Alligator Bioscience AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was kr-0.015. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-1,963.08 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-03), Alligator Bioscience AB's current stock price is kr0.0264. Alligator Bioscience AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was kr-1,963.08. Alligator Bioscience AB's Cyclically Adjusted Price-to-FCF of today is .


Alligator Bioscience AB  (OSTO:ATORX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Alligator Bioscience AB Cyclically Adjusted FCF per Share Related Terms


Alligator Bioscience AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Cyclically Adjusted FCF per Share Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1,945.50

Alligator Bioscience AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,943.04 -1,947.58 -1,945.50 -1,947.38 -1,963.08

OSTO:ATORX vs VRTX, REGN, MRNA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Cyclically Adjusted Price-to-FCF falls into.



Alligator Bioscience AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alligator Bioscience AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.015/134.6100*134.6100
=-0.015

Current CPI (Jun. 2026) = 134.6100.

Alligator Bioscience AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -3.802 101.138 -5.060
201612 -3.464 102.022 -4.570
201703 -5.038 102.022 -6.647
201706 -4.729 102.752 -6.195
201709 -5.294 103.279 -6.900
201712 -8.686 103.793 -11.265
201803 0.161 103.962 0.208
201806 -6.473 104.875 -8.308
201809 -8.271 105.679 -10.535
201812 -8.704 105.912 -11.062
201903 -6.545 105.886 -8.320
201906 -9.069 106.742 -11.437
201909 -11.635 107.214 -14.608
201912 -10.650 107.766 -13.303
202003 -10.205 106.563 -12.891
202006 -6.876 107.498 -8.610
202009 -6.741 107.635 -8.430
202012 -10.355 108.296 -12.871
202103 -7.076 108.360 -8.790
202106 -6.651 108.928 -8.219
202109 -5.571 110.338 -6.796
202112 -5.589 112.486 -6.688
202203 -3.430 114.825 -4.021
202206 -5.264 118.384 -5.986
202209 -5.412 122.296 -5.957
202212 -6.010 126.365 -6.402
202303 -6.293 127.042 -6.668
202306 -3.395 129.407 -3.532
202309 -2.058 130.224 -2.127
202312 -2.313 131.912 -2.360
202403 -3.514 132.205 -3.578
202406 -19,095.500 132.716 -19,368.013
202409 -25.146 132.304 -25.584
202412 -0.735 132.987 -0.744
202503 -2.542 132.825 -2.576
202506 -1.169 133.699 -1.177
202509 -0.313 133.480 -0.316
202512 -0.426 133.390 -0.430
202603 -0.048 133.560 -0.048
202606 -0.015 134.610 -0.015

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-1,963.08 mean?
Alligator Bioscience AB (OSTO:ATORX) has a Cyclically Adjusted FCF per Share of kr-1,963.08 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's Cyclically Adjusted FCF per Share too high?
Alligator Bioscience AB's current Cyclically Adjusted FCF per Share is kr-1,963.08.
How does Alligator Bioscience AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Alligator Bioscience AB's Cyclically Adjusted FCF per Share of kr-1,963.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Cyclically Adjusted FCF per Share is kr-1,963.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.03 — trading 164% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-1,963.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current Cyclically Adjusted FCF per Share is kr-1,963.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges 0RK9:UK7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.